Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind randomized placebo-controlled study of MK-0518 plus optimized background therapy in multidrug-resistant HIV infection
2005-005127-34Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing MK-0518 400 mg b.i.d. + OBT with Placebo + OBT (2 arms). Primary endpoints: Proportion of patients achieving HIV RNA <400 copies/mL at Week 16 and Safety and tolerability. Started Dec 2005; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-005127-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005127-34.